Media - Our stories

Explore our recent stories to see what drives us

02 August 2023

Completion of Joint Venture with Kyowa Kirin International

Grünenthal kicks off Joint Venture with Kyowa Kirin
Gabriel Baertschi

“With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”

Gabriel Baertschi

CEO, Grünenthal

On 1 August 2023, Grünenthal announced the successful completion of the Joint Venture with Kyowa Kirin International (KKI). The Joint Venture comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis.

As part of this Joint Venture a new standalone company has been created to market KKI’s established medicines portfolio. This company will be branded as Grünenthal Meds. Grünenthal is the majority shareholder of Grünenthal Meds and intends to acquire the remaining shares at the beginning of 2026.

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration (PDF)